He et al. [51] elucidated SNHG3's role in accelerating non-small-cell lung cancer (NSCLC) by downregulating miR-340-5p, linking elevated SNHG3 levels with increased HOXA10 expression and decreased miR-340-5p levels, contributing to adverse NSCLC outcomes. Here, SNHG3 is linked to non-small cell lung carcinoma.